3 December 2015 - Gilead Sciences set the price of its hepatitis C treatment sofosbuvir (Sovaldi) at $1000 a pill or $84 000 (£56 000; €79 000) for a single course of treatment to maximize revenue and to make it possible for it to charge even more for its follow-on combination drug, a US Senate finance committee has concluded.

For more details, go to: http://www.bmj.com/content/351/bmj.h6573?etoc=